Clinically relevant interactions between newer antidepressants and second-generation antipsychotics

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 5, 2014, Pages 721-746

  Spina, Edoardo ^a   De Leon, Jose ^b,c  

^a UNIVERSITY OF MESSINA   (Italy)

^b Eastern State Hospital   (United States)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

Drug interactions; New antidepressants; Pharmacodynamics; Pharmacokinetics; Second generation antipsychotics

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; ILOPERIDONE; LURASIDONE; MIRTAZAPINE; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; NEUROLEPTIC AGENT;

DRUG EFFECT; HUMAN; MAJOR DEPRESSION; OBSESSIVE COMPULSIVE DISORDER; PHARMACODYNAMICS; QT PROLONGATION; REVIEW; TORSADE DES POINTES; ANIMAL; DEPRESSIVE DISORDER, MAJOR; DRUG COMBINATION; DRUG INTERACTION; DRUG POTENTIATION; DRUG RESISTANCE; METABOLISM; OBSESSIVE-COMPULSIVE DISORDER; PERSONALIZED MEDICINE;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG INTERACTIONS; DRUG RESISTANCE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; INDIVIDUALIZED MEDICINE; OBSESSIVE-COMPULSIVE DISORDER;

EID: 84898441040     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.885504     Document Type: Review

References (122)

1. Stahl SM. Antidepressants. In: Stahl SM, editor. Stahl's essential psychopharmacology. 4th edition. Cambridge University Press, New York; 2013. p. 284-369
2. Stahl SM. Antipsychotic agents. In: Stahl SM, editor, Stahl's essential psychopharmacology. 4th edition. Cambridge University Press, New York; 2013. p. 129-236
3. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011;306:1359-69
4. Schirmbeck F, Esslinger C, Rausch F, et al. Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia. Psychol Med 2011;41:2361-73
5. Kantrowitz JT, Citrome L. Schizoaffective disorder: a review of current research themes and pharmacological management. CNS Drugs 2011;25:317-31
6. Farahani A, Correll CU. Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry 2012;73:486-96
7. Rummel C, Kissling W, Leucht S. Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials. Schizophr Res 2005;80:85-97
8. Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry 2010;197:174-9
9. Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 2006;11:622-32
10. Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol 2007;17:79-93
11. Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol 2013;16:557-74
12. Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 2007;68:826-31
13. Shelton RC, Papakostas GI. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand 2008;117:253-9
14. Nelson J, Papakostas G. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009;166:980-91
15. Nemeroff CB, Preskorn S, Devane CL. Antidepressant drug-drug interactions: clinical relevance and risk management. CNS Spectr 2007;12(Suppl 7):1-13
16. Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008;30:1206-27
17. Schellander R, Donnerer J. Antidepressants: clinically relevant drug interactions to be considered. Pharmacology 2010;86:203-15
18. Spina E, Trifirò G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs 2012;26:39-67
19. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007;100:4-22
20. Conley RR, Kelly DL. Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. Psychopharmacol Bull 2007;40:77-97
21. Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome P450 enzymes and relevance for drug-drug interactions. Curr Drug Metab 2008;9:410-18
22. Kennedy WK, Jann MW, Kutscher EC. Clinically significant drug interactions with atypical antipsychotics. CNS Drugs 2013;12:1021-48
23. Spina E. Drug interactions. In: Shorvon S, Perucca E, Engel J, editors, Treatment of epilepsy. 3rd edition. Wiley-Blackwell Publishing Ltd, Oxford; 2009. p. 361-77
24. Cozza KL, Armstrong SC, Oesterheld JR. Concise guide to drug interaction principles for medical practice: cytochrome P450s, UGTs, P-glycoproteins. 2nd edition. American Psychiatric Association, Washington, DC; 2003
25. Tarazi FI, Stahl SM. Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother 2012;13:1911-22
26. Bobo VW. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol 2013;6:61-91
27. Lin JH. Transporter-mediated drug interactions. Clinical implications and in vitro assessment. Expert Opin Drug Metab Toxicol 2007;3:81-92
28. O'Brien FE, Dinan TG, Griffin BT, Cryan JF. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol 2012;165:289-312
29. Moons T, de Roo M, Claes S, Dom G. Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics 2011;12:1193-211
30. Akamine Y, Yasui-Furukori N, Ieiri I, Uno T. Psychotropic drug-drug interactions involving P-glycoprotein. CNS Drugs 2012;26:959-73
31. Citrome L. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2012;66:356-68
32. Gibb A, Deeks ED. Vortioxetine: first global approval. Drugs 2014;74:135-45
33. Labbate LA, Fava M, Rosenbaum JF, et al. Handbook of psychiatric drug therapy. Lippincott Williams & Wilkins, Philadelphia; 2010
34. Pompili M, Serafini G, Innamorati M, et al. Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review. World J Biol Psychiatry 2013;14:412-31
35. de Leon J, Santoro V, D'Arrigo C, Spina E. Interactions between antiepileptics and second-generation antipsychotics. Expert Opin Drug Metab Toxicol 2012;8:2-24
36. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002;3:13-37
37. Centorrino F, Baldessarini RJ, Kando J, et al. Serum concentrations of clozapine and its metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 1994;151:123-5
38. Centorrino F, Baldessarini RJ, Frankenburg FR, et al. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 1996;153:820-3
39. Spina E, Avenoso A, Facciolà G, et al. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int Clin Psychopharmacol 1998;13:141-5
40. Diaz FJ, Santoro V, Spina E, et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry 2008;41:81-91
41. Spina E, Avenoso A, Scordo MG, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol 2002;22:419-23
42. Bondolfi G, Eap CB, Bertschy G, et al. The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychiatric patients. Pharmacopsychiatry 2002;35:50-6
43. Gossen D, de Suray JM, Vandenhanden F, et al. Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci 2002;4:1-6
44. Potkin SG, Thyrum PT, Alva G, et al. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J Clin Psychopharmacol 2002;22:174-82
45. Castberg I, Skogvoll E, Spigset O. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J Clin Psychiatry 2007;68:1540-5
46. Waade RB, Christensen H, Rudberg I, et al. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Ther Drug Monit 2009;31:233-8
47. Paul S, Cooke BK, Nguyen M. Glossopharyngeal dystonia secondary to a lurasidone fluoxetine CYP-3A4 interaction. Case Rep Psychiatry 2013;2013:136194
48. Spina E, Avenoso A, Facciolà G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit 2001;23:223-7
49. Saito M, Yasui-Furukori N, Nakagami T, et al. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. J Clin Psychopharmacol 2005;25:527-32
50. Spina E, Avenoso A, Salemi M, et al. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. Pharmacopsychiatry 2000;33:213-17
51. Wetzel H, Anghelescu I, Szegedi A, et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 1998;18:2-9
52. Nemoto K, Mihara K, Nakamura A, et al. Effects of paroxetine on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit 2012;34:188-92
53. Azuma J, Hasunuma T, Kubo M, et al. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. Eur J Clin Pharmacol 2012;68:29-37
54. Hiemke C, Weighmann H, Hartter S, et al. Elevated serum levels of clozapine after addition of fluvoxamine. J Clin Psychopharmacol 1994;14:279-81
55. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-74
56. Kuo FJ, Lane HY, Chang WH. Extrapyramidal symptoms after addition of fluvoxamine to clozapine. J Clin Psychopharmacol 1998;18:483-4
57. Szegedi A, Anghelescu I, Wiesner J, et al. Addition of low-dose of fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 1999;32:148-53
58. Fabrazzo M, La Pia S, Monteleone P, et al. Fluvoxamine increases plasma and urinary levels of clozapine and its major metabolites in a time-and dose-dependent manner. J Clin Psychopharmacol 2000;20:708-10
59. Olesen OV, Linnet K. Fluvoxamine-clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. J Clin Psychopharmacol 2000;20:35-42
60. Lammers CH, Deuschle M, Weigmann H, et al. Coadministration of clozapine and fluvoxamine in psychotic patients: clinical experience. Pharmacopsychiatry 1999;2:76-7
61. Lu ML, Lane HY, Chen KP, et al. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry 2000;61:594-9
62. Lu ML, Lane HY, Lin SK, et al. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 2004;65:766-71
63. Weigmann H, Gerek S, Zeisig A, et al. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 2001;23:410-13
64. de Jong J, Hoogenboom B, van Troostwijk LD, de Haan L. Interaction of olanzapine with fluvoxamine. Psychopharmacology (Berl) 2001;155:219-20
65. Hiemke C, Avi P, Jabarin M, et al. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol 2002;22:502-6
66. Chiu CC, Lane HY, Huang MC, et al. Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia. J Clin Pharmacol 2004;44:1385-90
67. Albers LJ, Ozdemir V, Marder SR, et al. Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy. J Clin Psychopharmacol 2005;25:170-4
68. D'Arrigo C, Migliardi G, Santoro V, et al. Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia. Pharmacol Res 2005;52:497-501
69. Spina E, D'Arrigo C, Migliardi G, et al. Plasma risperidone concentrations during combined treatment with sertraline. Ther Drug Monit 2004;26:386-90
70. Chong SA, Tan CH, Lee HS. Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports. J Clin Psychopharmacol 1997;17:68-9
71. Pinninti NR, de Leon J. Interaction of sertraline with clozapine. J Clin Psychopharmacol 1997;17:119-20
72. Pierson K, Addington D, Addington J, Patten S. Serum monitoring of antipsychotic drug levels during concomitant administration of sertraline and antipsychotic medication. Can J Psychiatry 2006;51:715-18
73. Von Moltke LL, Greenblatt DJ, Grassi JM, et al. Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry 1999;46:839-49
74. Von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001;29:1102-9
75. Taylor D, Ellison Z, Ementon Shaw L, et al. Co-administration of citalopram and clozapine: effect on plasma clozapine levels. Int Clin Psychopharmacol 1998;13:19-21
76. Avenoso A, Facciolà G, Scordo MG, et al. No effect of citalopram on plasma concentrations of clozapine, risperidone and their active metabolites in patients with chronic schizophrenia. Clin Drug Invest 1998;16:393-8
77. Botts S, Diaz FJ, Santoro V, et al. Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1453-8
78. Oganesian A, Shilling AD, Young-Sciame R, et al. Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities. Psychopharmacol Bull 2009;42:47-63
79. Amchin J, Zarycranski W, Taylor KP, et al. Effect of venlafaxine on the pharmacokinetics of risperidone. J Clin Pharmacol 1999;39:297-309
80. Repo-Tiihonen E, Eloranta A, Hallikainen T, et al. Effects of venlafaxine treatment on clozapine plasma levels in schizophrenic patients. Neuropsychobiology 2005;51:173-6
81. Lobo ED, Bergstrom RF, Reddy S, et al. In vitro and in vivo evaluations of cytochrome P4501A2 interactions with duloxetine. Clin Pharmacokinet 2008;47:191-202
82. Englisch S, Knopf U, Scharnholz B, et al. Duloxetine for major depressive episodes in the course of psychotic disorders: an observational clinical trial. J Psychopharmacol 2009;23:875-82
83. Santoro V, D'Arrigo C, Micò U, et al. Effect of adjunctive duloxetine on the plasma concentrations of clozapine, olanzapine and risperidone in patients with psychotic disorders. J Clin Psychopharmacol 2010;30:634-6
84. Hendset M, Molden E, Enoksen TB, et al. The effect of coadministration of duloxetine on steady-state serum concentration of risperidone and aripiprazole: a study based on therapeutic drug monitoring data. Ther Drug Monit 2010;32:787-90
85. Wienkers LC, Allievi C, Hauer MJ, et al. Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Drug Metab Dispos 1999;27:1334-40
86. Spina E, Avenoso A, Scordo MG, et al. No effect of reboxetine on plasma concentrations of clozapine, risperidone and their active metabolites. Ther Drug Monit 2001;23:675-8
87. Stormer E, von Moltke LL, Shader RI, et al. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 2000;28:1168-75
88. Loonen AJ, Doorschot CH, Oostelbos MC, et al. Lack of drug interaction between mirtazapine and risperidone in psychiatric patients. Eur Neuropsychopharmacol 1999;10:51-7
89. Zoccali R, Muscatello MR, La Torre D, et al. Lack of pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacol Res 2003;48:411-14
90. Boulton DW, Balch AH, Royzman K, et al. The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder. J Psychopharmacol 2010;24:537-46
91. Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 2013;10:e1001403
92. Rothschild AJ. Challenges in the treatment of major depressive disorder with psychotic features. Schizophr Bull 2013;39:787-96
93. Silva MT, Zimmermann IR, Galvao TF, et al. Olanzapine plus fluoxetine for bipolar disorder: a systematic review and meta-analysis. J Affect Disord 2013;146:310-18
94. Komossa K, Depping AM, Meyer M, et al. Second generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev 2010;12:CD008141
95. Hecht EM, Landy DC. Alpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia; a meta-analysis. Schizophr Res 2012;134:202-6
96. Vieta E, Günther O, Locklear J, et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2011;14:1029-49
97. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 2013;170:1249-62
98. Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand 2010;121:404-14
99. J€onsson AK, Spigset O, Hägg S. Venous thromboembolism in recipients of antipsychotics: incidence, mechanisms and management. CNS Drugs 2012;26:649-62
100. Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust 2007;187:361-5
101. Ables AZ, Nagubilli R. Prevention, recognition, and management of serotonin syndrome. Am Fam Physician 2010;81:1139-42
102. Lin PY, Hong CJ, Tsai SJ. Serotonin syndrome caused by ziprasidone alone. Psychiatry Clin Neurosci 2010;64:338-9
103. Rim CL, Gitlin MJ. Ziprasidone, monoamine oxidase inhibitors, and the serotonin syndrome. J Clin Psychopharmacol 2010;30:470-1
104. El-Okdi NS, Lumbrezer D, Karanovic D, et al. Serotonin syndrome after the use of tramadol and ziprasidone in a patient with a deep brain stimulator for Parkinson disease. Am J Ther 2013. [Epub ahead of print]
105. Himmighoffen H, Seifritz E, Boeker H. Serotonin syndrome after discontinuation of olanzapine in a combined treatment with duloxetine-case report. Pharmacopsychiatry 2011;44:75-6
106. Stevenson E, Schembri F, Green DM, et al. Serotonin syndrome associated with clozapine withdrawal. JAMA Neurol 2013;70:1054-5
107. Rittmannsberger H, Werl R. Does aripiprazole protect from serotonin syndrome? Psychiatr Danub 2012;24:100-1
108. Weiner E, Ball MP, Buchholz AS, et al. Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis. J Clin Psychiatry 2012;73:95-102
109. Englisch S, Morgen K, Meyer-Lindenberg A, Zink M. Risks and benefits of bupropion treatment in schizophrenia: a systematic review of the current literature. Clin Neuropharmacol 2013;36:203-15
110. Koliscak LP, Makela EH. Selective serotonin reuptake inhibitor-induced akathisia. J Am Pharm Assoc 2009;49:e28-36
111. Rummel-Kluge C, Komossa K, Schwarz S, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 2012;38:167-77
112. Kumar R, Sachdev PS. Akathisia and second-generation antipsychotic drugs. Curr Opin Psychiatry 2009;22:293-9
113. Heist EK, Ruskin JN. Drug-induced arrhythmia. Circulation 2010;122:1426-35
114. Kogut C, Breden Crouse E, Vieweg V, et al. Selective serotonin reuptake inhibitors and torsade de pointes: new concepts and new directions derived from a systematic review of cases reports. Ther Adv Drug Saf 2013;4:189-98
115. Poluzzi E, Raschi E, Koci A, et al. Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. Drug Saf 2013;36:467-79
116. Vieweg WV, Hasnain M, Hancox JC, et al. Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports. Psychopharmacology (Berl) 2013;228:515-24
117. Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syndrome. Pharmacol Rev 2010;62:760-81
118. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24:62-9
119. Potkin SG, Preskorn S, Hochfeld M, et al. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone. J Clin Psychopharmacol 2013;33:3-10
120. Gahr M, Freudenmann RW, Connemann BJ, et al. Agomelatine and hepatotoxicity: implications of cumulated data derived from spontaneous reports of adverse drug reactions. Pharmacopsychiatry 2013;46:214-20
121. Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry 2013. [Epub ahead of print]
122. de Leon J. Evidence-based medicine versus personalized medicine: are they enemies? J Clin Psychopharmacol 2012;32:153-64